AbbVie Inc. · ABBV · FY2026 Q2 · Calendar Q3 2026

AbbVie raises revenue outlook as immunology and pipeline momentum continue

The supplied analysis supports a constructive but conditional view: immunology growth, new approvals, and pipeline expansion strengthen AbbVie’s growth trajectory, while regulatory, competitive, and integration risks remain material.

Why did ABBV fall 2.5% after beating EPS estimates in FY2026 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $468.77B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $3.65 Consensus $3.61
EPS surprise +1.1% Reported versus consensus
Reported revenue $16.99B Consensus $16.80B
Revenue surprise +1.1% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move -2.5% Event window
SPY move +0.7% Same window
Abnormal move -3.2% Stock minus SPY
Volume 1.2× Versus trailing sessions
Subsequent drift +1.8% Up to 20 sessions
ABBVSPY benchmark

Ask FN2 about ABBV FY2026 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Relative to the prior-quarter analysis, AbbVie’s Q2 update added a $300 million full-year revenue-guidance increase, reported continued strength in SKYRIZI and RINVOQ, and highlighted the Apogee acquisition and additional approvals as new sources of pipeline depth.

Guidance delta

Management raised full-year revenue guidance by $300 million; the supplied analysis does not specify the resulting range.

Key takeaways

  • Q2 results exceeded expectations, according to the supplied transcript analysis.
  • SKYRIZI and RINVOQ delivered more than 20% growth across multiple indications.
  • New approvals and late-stage programs broadened the growth pipeline.
  • The Apogee Therapeutics acquisition adds immunology and dermatology assets.
  • Management remained confident while highlighting regulatory and competitive execution risks.

Management priorities

  • Extend SKYRIZI through subcutaneous induction dosing and additional indications.
  • Advance RINVOQ approvals in vitiligo and alopecia areata.
  • Launch tevapadone and build the Parkinson's portfolio.
  • Integrate Apogee assets and progress late-stage immunology, oncology, and neuroscience programs.

Follow ABBV with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ABBV EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $2.76 Q4 '23 actual $2.79, beat Q1 '24 estimate $2.26 Q1 '24 actual $2.31, beat Q2 '24 estimate $2.57 Q2 '24 actual $2.65, beat Q3 '24 estimate $2.92 Q3 '24 actual $3.00, beat Q2 '25 estimate $2.88 Q2 '25 actual $2.97, beat Q3 '25 estimate $1.77 Q3 '25 actual $1.86, beat Q4 '25 estimate $2.65 Q4 '25 actual $2.71, beat Q1 '26 estimate $2.59 Q1 '26 actual $2.65, beat Q2 '26 estimate $3.61 Q2 '26 actual $3.65, beat Q3 '26 estimate $3.73 Q3 '26 actual $3.82, beat Q4 '26 estimate $4.00 Q1 '27 estimate $3.32
Show less

Analyst Consensus ?

ConsensusBuy44 ratings
Bullish3170.4%
Neutral1227.3%
Bearish12.3%

Analyst 52W Price Targets

$286.2Current
$127Low
$230.19Average
$349High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainNov 2, 2026
UBS Neutral NeutralMaintainNov 2, 2026
RBC Capital Outperform OutperformMaintainNov 2, 2026
Morgan Stanley Overweight OverweightMaintainNov 2, 2026
Leerink Partners Outperform OutperformMaintainNov 2, 2026
Show 39 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $286.2. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Piper SandlerDavid Amsellem$349$289.2 +21.9%Nov 18, 2026
BMO CapitalAnalyst unavailable$315$285.67 +10.1%Nov 4, 2026
Cantor FitzgeraldCarter Gould$325$287.17 +13.6%Nov 2, 2026
RBC CapitalTrung Huynh$330$288.91 +15.3%Nov 2, 2026
BernsteinCourtney Breen$275$287.99 -3.9%Nov 2, 2026
See 104 more

Track every rating change on ABBV the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism.…

Historical context

All ABBV earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ABBV recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-31T15:07:17.198579+00:00
  2. FN2 earnings calendar · 2026-09-05T01:23:14.965082+00:00
  3. Polygon adjusted daily market bars · 2026-09-23T07:40:52.391685+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-23T07:40:52.388827+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-23. For educational purposes only; not investment advice.